Meeting
2018 Gastrointestinal Cancers Symposium
Activity and safety of Nab-FOLFIRI and Nab-FOLFOX as first-line treatment for metastatic pancreatic cancer (phase II NabucCO study).
Authors
Elisa Giommoni
Azienda Ospedaliero Universitaria Careggi, Firenze, Italy
Elisa Giommoni , Evaristo Maiello , Vanja Vaccaro , Ermanno Rondini , Caterina Vivaldi , Giampaolo Tortora , Laura Toppo , Guido Giordano , Tiziana Pia Latiano , Lorenzo Antonuzzo , Cinzia Lamperini , Luca Boni , Francesco Di Costanzo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02109341
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 351)
DOI
10.1200/JCO.2018.36.4_suppl.351
Abstract #
351
Poster Bd #
G12
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Alternating gemcitabine/nab-paclitaxel (GA) and 5-FU/leucovorin/irinotecan (FOLFIRI) as first-line treatment for de novo metastatic pancreatic cancer (MPC): Safety and effect.
First Author: Brett A. Schroeder
Poster
2020 ASCO Virtual Scientific Program
HGCSG 1803: Single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first-line treatment.
First Author: Shintaro Nakano
Poster
2024 ASCO Gastrointestinal Cancers Symposium
De-escalation and dose density in real-world patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX in the first line.
First Author: Syvart Dennen
Poster
2023 ASCO Annual Meeting
Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA).
First Author: Haeseong Park